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Summary Epidermal growth factor (EGF). its related peptide transforming growth factor (TGF-a) and their
common receptor (EGFR) have been implicated in the control of cell proliferation and differentiation in the
gastrointestinal epithelium and may play an important role in gastric carcinogenesis. We compared the
immunohistochemical expression and topographic distribution of these peptides using Western blot analysis in
gastric carcinoma precursor lesions and in non-cancer tissue. We observed: (i) increased and extended
expression of TGF-a in normal mucosa and hyperplasia in carcinoma fields compared 'with non-cancer
controls: (ii) increased expression of EGFR in intestinal metaplasia (IM) from carcinoma fields compared with
controls; (iii) EGF expression was not detected in normal mucosa and only weakly in IM; (iv) coexpression of
TGF-a EGFR and EGF EGFR was higher in intestinal metaplasia in carcinoma fields than in non-cancer
controls. We conclude that altered expression of TGF-a EGFR is associated with morphological changes
dunrng gastric carcinogenesis. In this regard increased expression of TGF-a is a very early event which is
subsequently followed by up-regulation of EGFR and this has important biological and clinical implica-
tions.
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Gastric carcinogenesis is a stepwise process which starts with
molecular changes in normal cells resulting in phenotypic
adaptation. In this regard chronic gastritis is one of the
earliest identifiable histological abnormalities and may lead
to intestinal metaplasia (IM), dysplasia and ultimately
adenocarcinoma (Correa, 1988). The underlying mechanisms
that control this process are not as yet fully understood. The
majority of gastric carcinomas appear to be caused by
environmental factors resulting in mucosal damage and
repair (Parsonnet et al., 1991; UK Subgroup of the ECP-
Euronut-IM Study Group, 1992; Pignatelli et al., 1993). This
pleomorphic response is regulated in part by inhibitory and
stimulatory molecules derived from proto-oncogenes and
tumour-suppressor genes (Tahara, 1993). Growth factors are
important regulators of cell differentiation and proliferation
and play an important role in maintaining the integnty of the
epithelium. Increased expression in cells or aberrant topo-
graphical distribution of the growth-regulatory peptides
epidermal growth factor (EGF) and transforming growth
factor X (TGF-uc) and their receptor (EGFR) has been de-
scribed in the gastrointestinal epithelium associated with
mitogenesis and carcinogenesis (Goodlad and Wright, 1990;
Jankowski. 1992; Nasim et al.. 1992; Filipe and Jankowski,
1993). Human TGF-a has been mapped to chromosome 2 to
the short arm region 2pll -2pl3. and it is known that
chromosome 2 contains other genes that are involved in
growth regulation and tumorigenesis. EGFR has been found
to be overexpressed at high frequency in a wide range of
tumours. Increased expression of TGF-x is frequent in gastric
carcinoma (60%). particularly the intestinal type of car-
cinoma, but EGFR overexpression was less frequent (18%)
in our series (Goodlad and Wright. 1990; Jain et al., 1991;
Lemoine et al.. 1991). Coexpression of EGF and its receptor
(EGFR) is correlated with progression of these tumours and
poor prognosis (Yonemura et al.. 1991. 1992).
The expression of growth factors is deregulated in invasive
neoplasms but few data are available with regard to their
expression in the early stages of tumorigenesis.
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The purpose of this study was to assess the altered expres-
sion of growth factors EGF and TGF-x and their common
receptor EGFR in the precursor lesions to gastric carcinoma
and the possible role of such altered expression in the multi-
step process of malignancy. In addition. we were interested in
assessing whether immunoreactivity to growth factors and
their receptors corresponded with normal- or aberrant-sized
protein products by Western blot analysis.
Materials and methods
Formalin-fixed paraffin-embedded samples from 16 stomachs
resected for early stage TI gastric carcinoma and nine from
advanced gastnrc carcinomas were available: 19 intestinal, 4
diffuse and two mixed (Lauren, 1965). Non cancer control
biopsies were obtained from gastric ulcer or chronic gastritis
patients (n = 56). The non-carcinoma control samples in-
cluded specimens of normal histology (n = 41) and intestinal
metaplasia (n = 15).
Carcinoma field changes from the 16 TI gastric carcinomas
included histologically normal mucosa (n = 16). hyperplasia
(n = 14), intestinal metaplasia (n = 17) and dysplasia (n = 10.
of which seven cases were high grade) (Riddel et al..
1983).
Carcinoma field changes from the nine advanced gastric
carcinomas included histologically normal mucosa (n = 7),
hyperplasia (n = 3), intestinal metaplasia (n = 5) and dys-
plasia (n = 4, of which two cases were high grade).
The total numbers of carcinoma field lesions were as fol-
lows: normal, 23; intestinal metaplasia, 22; hyperplasia, 17;
dysplasia, 14, of which nine lesions were high grade.
Immunostaining
All material retrieved was formalin fixed and paraffn em-
bedded from Guy's Hospital archives.
The primary antibodies used were: mouse anti-TGF-m, Ab-
2, clone 213-94 (Oncogene Science), used on sections at a
concentration of 0.33 1tg ml- , overnight at 4'C; rabbit anti-
EGFR, 12E (a gift- from W Gullick), used on sections at a
concentration of 8 jig ml-'. for 1 h at room temperature; andGrwt hd expresson in gastric carcinoma
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rabbit anti-EGF. Ab-3 (Oncogene Science), used on sections
at a concentration of 5 jig ml1-' at room temperature for
1 h.
Three micron paraffin sections were attached to slides
using poly-L-lysine (Sigma). TGF-a sections were oven dned
(30 min, 60'C); EGFR and EGF were air dried. Following
rehydration in phosphate-buffered saline (PBS). endogenous
peroxidase activity was blocked with 0.3% hydrogen per-
oxide (in five parts methanol for EGFR and EGF sections).
Sections were then incubated in normal goat (TGF-a), calf
(EGFR) or swine (EGF) serum before incubation in the
primary antibody. Subsequent incubation in biotinylated
goat anti-mouse (TGF-a) or swine anti-rabbit (EGFR, EGF)
serum preceded incubation with the Dako ABC-Complex kit
(TGF-x), Dako streptavidin ABC kit (EGFR) or streptavidin
horseradish peroxidase (EGF) (Oncogene Science). Peroxi-
dase activity was developed with diaminobenzidine (Sigma).
Slides were lightly counterstained with Carrazzi haematoxy-
lin. For negative controls primary antibody was replaced
with PBS. Positive controls were also run.
Interpretation ofimmunostaining
This was carried out by two independent observers blind to
the clinical and histological data (MIF and MO). Positive
immunoreactivity for TGF-z, EGFR and EGF was found in
the cell membranes and cytoplasm. Sections were only con-
sidered negative if no staining was seen in these cellular
locations. For each lesion. expression of each growth factor/
receptor was carried out using a seniquantitative scoring
method for the following parameters: (i) intensity of staining,
0-3 for negative. weak, moderate and strong; (ii) extent of
expression, 0-3 for negative, focal (up to 30% cells positive),
patchy (30-50% of cells positive) or extensive (>50% cells
positive); (iii) location of TGF-a, EGFR and EGF immuno-
reactivity within gastric glands in each lesion was assessed by
dividing each gland into compartments, upper third, middle
and lower third, or all three areas, upper, middle and lower.
There was strong agreement in the interpretation of these
parameters between the two observers (MIF and MO). and
in a few cases where disagreement occurred an agreed score
was achieved.
Statistical analysis
The Kruskal-Wallis test was conducted to determine the
different expression patterns of lesions in terms of intensity
and extent of expression. This statistical test was chosen as
the data were not parametnrc. The Z-values obtained are a
better indicator of how the expression varied between lesions
than does a mere comparison of the median expression of
score values, as they take into account the range of expres-
sion between lesions of the same type. A positive score
indicates that the median and range of that particular group
of lesions is different when compared with the inter-group
variation. The chi-squared test was also carried out to assess
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quantitative differences in the proportion of lesions express-
ing specific growth factors.
Western blot analysis
Proteins were extracted from fresh-frozen specimens, includ-
ing normal mucosa (n = 3). intestinal metaplasia (n = 3) and
well or moderately/poorly differentiated gastric carcinomas
(n = 4). Samples were homogenised in sodium dodecyl sul-
phate,glycine,Tris gel loading buffer in the presence of a
protease inhibitor for 2 mmn. After centrifugation at 30 000g
for 20 min, the resultant supernatant was frozen. The protein
concentration was estimated by light spectrophotometry at
595 nm according to the Bradford method (Jankowski,
1994a).
Prior to running the proteins in a 15% acrylamide gel
(7.5% gel was used for EGFR) at low voltage (8 V cm-'),
P-mercaptoethanol was added to the samples and these were
heated at 100°C for 3 min. Thirty micrograms of total pro-
tein from each sample was loaded in each gel lane.
Using a Bio-Rad trans-blot apparatus (Protean II. Bio-
Rad. London, UK) the proteins were transferred from the gel
to a compound nylon-nitrocellulose membrane (Satonros,
London, UK). Once the transfer was completed the mem-
brane and gel were removed and the gel was placed in
Coomassie brilliant blue to assess the efficiency of the protein
transfer.
The membrane was stained with Ponceau S in order to
mark the molecular weight standard with a waterproof pen-
cil. Subsequently. the membrane was fixed in 0.2% glutaral-
dehyde-PBS for 45min with gentle agitation.
The membrane was then washed in PBS +0.1I% Tween.
The membrane was then blocked in 3% bovine serum
albumin (BSA) in PBS for I h. After washing, the membrane
was incubated in 1:750 diluted primary antibody (Ab-2) for
2 h followed by incubations with biotinylated rabbit and
anti-mouse antibody (Dako. London, UK) for 1 h and ABC
peroxidase complex (Dako) (5 mg ml ')for 30 min and DAB
(0.3 mg ml-') for 3 min. Negative control expenrments
included blots incubated without either the primary or the
secondary antibody, and positive controls included primary
breast and colonic adenocarcinomas. In addition, three
paired samples ofgastric tissue were incubated in plastic bags
of 5 ml volume with TGF-a antibody at 1:750 dilution with
or without TGF-a 50 amino acid peptide (Sigma UK) at
50jLg ml'.
Results
Immunohistochemistry
Intensity of immunoreactivity TGF-a expression was signifi-
cantly greater in histologically normal mucosa from car-
cinoma fields than in normal control mucosa from biopsies
(chi-squared test. P<0.01). In contrast, levels of TGF-a
Table I Intensitv of TGF-a expression
Normal mucosa
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expression in intestinal metaplasia from carcinoma fields
were similar to those seen in intestinal metaplasia from non-
cancer patients (control biopsies). Dysplasia from carcinoma
fields showed lower levels of TGF-a expression in both high-
grade and low-grade dysplasia than in all other precursor
lesions (but the numbers were too few to allow formal stati-
stical analysis). Based on Kruskall-Wallis analysis, TGF-a
expression was greatest in histological epithelium from car-
cinoma fields (Z = 2.84) and lowest in normal control speci-
mens (Z= -2.16) (Table I).
EGFR expression was moderate to weak in most types of
lesion, with no difference between histologically normal
mucosa from carcinoma fields and non-cancer controls.
However, intestinal metaplasia from carcinoma fields showed
significantly higher expression of EGFR than its control
(P<0.1; Z= 3.8 vs Z= 1.07) (Table II).
Most lesion types failed to show EGF expression, with the
exception of intestinal metaplasia, which presented slightly
higher z-values than all other lesions.
Extent ofimnmunoreactivitv TGF-a expression was extensive
in intestinal metaplasia in both carcinoma fields and non-
cancer controls. Extensive immunoreactivity was also seen in
hyperplasia and normal mucosa in carcinoma fields but was
patchy compared with the corresponding controls (P<0.1).
A similar trend was seen with EGFR expression. In dysplas-
tic mucosa both TGF-c and EGFR staining was predomin-
antly patchy/focal. The pattern of EGF expression was
dwarfed by the high rate of negative cases, but when detected
it tended to be patchy in all lesion types.
Positional TGF-c and EGFR immunoreactivity within gland
compartments The positional expression patterns of precur-
sor lesions and controls were very clear for TGF-a and
EGFR (Tables III and MV). In the majority of normal
mucosas from non-cancer control biopsies, TGF-x immuno-
reactivity was confined to the upper gland compartment
(95%) compared with only 22% of normal mucosas in car-
cinoma fields (Figures 1 and 2). None of the normal control
biopsies expressed TGF-x throughout the whole glandular
epithelium compared with 77% of 'normal' mucosa from
carcinoma fields. These differences between distnrbution of
TGF-a in the upper gland compartment are less marked for
intestinal metaplasia, being 64% and 77% in IM in car-
cinoma field lesions and IM non-cancer controls respectively.
Most dysplastic lesions had further reductions in TGF-a in
the upper gland compartment (58%).
The positional patterns of EGFR expression are similar to
but more marked than those revealed with TGF-a. In parti-
cular, an extensive EGFR expression throughout the whole
glandular epithelium is seen in intestinal metaplasia in car-
cinoma fields (80%) compared with controls (50%) (Figures
3 and 4). In addition, the intensity of EGFR expression
increases serially in normal gastric mucosa from controls to
normal in gastric cancer fields. intestinal metaplasia and
intestinal metaplasia from carcinoma stomachs and to dys-
plasia. In this regard a specimen of dysplastic mucosa with
IM showed markedly increased EGFR expression (Figure
5).
EGF was not immunohistochemically detectable in normal
mucosa but was weakly detectable in intestinal metaplasia.
Coexpression High levels of TGF-m/EGFR coexpression
were observed in the precursor lesions with the exception of
hyperplasia. In particular, the median intensity of immuno-
reactivity was twice as high in normal mucosa from car-
cinoma fields as in non-cancer controls, but no difference was
detected in intestinal metaplasia. Conversely, in the few speci-
Table I Intensity of EGFR expression
Normal mucosa Intestinal metaplasia Hyperplasia D-splasia
Intensity of Control Ca field Control Ca field Ca field Ca field
staining (n = 41) (n =20) (n 15) (n = 22) (n =17) (n 13)
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Table m Positional expression of TGF-a
Normal mucosa Intestinal metaplasia Hyperplasia Dysplasia
Zone sho%wing Control Ca field Control Ca field Ca field Ca field
expression (n =39) (n =22) (n = 13) (n = 14) (n = 12) (n = 121)
Top + middle
+ lower
*-
(77%) (23%) (36%) (50%) (33%)
Middle + lower ..
(5%) (25%)
00000~ ~ ~ ~ 000@0 00
00O *-
Upper gland *...
@0000
Surface +
foveolar .
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Table IV Positional expression of EGFR
Normal mucosa Intestinal metaplasia Hyperplasia Dysplasia
Zone showing Control Ca field Control Ca field Ca field Ca field
expression (n =34) (n = 15) (n = 12) (n =20) (n =8) (n =8)
Top + middle m v *-_v
+ lower
(9%) (33%) (50%) (80%) (63%) (75%)
Middle + lower v v v
(7%) (5%) (12%)
000"~~~~~~~
Upper gland _
*@O
Surface +
foveolar .
epithelium .
(91%) (60%) (50%) (15%) (25%) (25%)
Fugwe 1
50Pm.
TGF-z expression in normal gastric epithelium. Bar =
Fugwe 2 TGF-a extended expression in 'normal' gastric
epithelium in carcinoma fields. Bar = 100pm.
Fugwe 3 EGFR expression in intestinal metaplasia in non-
cancer field. Bar = 50pm.
mens which had EGF/EGFR coexpression, this was similar
in normal mucosa from carcnoma fields and non-cancer con-
trols but was higher in intestinal metaplasia from carcinoma
fields than in their counterparts in non-ancer controls.
Western blot analysis EGF immunoreactivity corresponded
with molecular weight species of 6 kDa, however larger
molecular weight bands were also present at 9, 14 and
18 kDa. This may indicate a common epitope of the EGF
antibody with EGF and its precursors or other related
members of the EGF family (Figure 6).
TGF-x immunoreactivity was strongest at 6 kDa (Figure
7). It is also evident that the signet ring carcinoma has
reduced immunoreactivity compared with the well-
differentiated carcinomas and the intestinal metaplasia. In
addition, a competition reaction was performed in which
prior incubation of TGF-x (TGF-a 50 amino acid peptide,
Sigma, UK) markedly reduced the subsequent immunoreac-
tivity in the Western blot compared with unblocked paired
specimens (Figure 8).
EGFR immunoreactivity was maximal at 170 kDa,
indicating specificity for the mature receptor (Figure 9).
Expression ofEGF, TGF-x and EGFR
Our data support the hypothesis that increased EGFR and
TGF-a expression is associated with early events in gastrici Growth facxor iex n - cac
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A B C
Fiwe 6 EGF has multiple immunoreactive bands between 6
and 14 kDa suggesting cross-reaction with EGF and its precur-
sors. A, Carcinoma; B, Intestinal metaplasia; C, NAD.
Fugwe 4 EGFR extended expression in intestinal metaplasia in
carcinoma field. Bar =5O nm.
a b c d e
Figwe 5 EGFR extended expression in dysplastic epithelium.
Bar = 50gm.
Fmgwe 7 TGF-a corresponds to 6 kDa in carcinoma and intes-
tinal metaplasia (IM). All specimens have similar immunoreac-
tivity except the poorly differentiated (signet ring) carcinoma,
which shows markedly reduced staining. a and b, carcinoma; c
and d, intestinal metaplasia; e, poorly differentiated car-
cinoma.
tumorigenesis. Altered expression of TGF-a and EGFR in
terms of greater intensity of immunostaining and extended
involvement of the glandular epithelium occurred at an ear-
lier stage in histologically normal mucosa and glandular
hyperplasia in carcinoma fields than in non-cancer con-
trols.
Up-regulation of TGF-a appears to be one of the earliest
events during gastric tumorigenesis as it is induced in normal
mucosa adjacent to cancer. Subsequently, EGFR expression
is up-regulated during the generation of metaplastic
epithelium.
Mechanisms ofgrowthfactor-enhanced twnorigenesis
Growth factors are components of signal transduction path-
ways which have a considerable spectrum of biological
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Figure 9 EGFR shows strong immunoreactivity bands at
160-170 kDa for well-differentiated adenocarcinoma and weaker
bands for intestinal metaplasia. A and B. carcinoma; C and D,
intestinal metaplasia.
activity, such as control of cell proliferation, differentiation,
apoptosis, transformation and neovascularisation. In addi-
tion, EGF and TGF-a may regulate the transition rate
between G2-phase and mitosis of the cell cycle. TGF-a has a
greater mitogenic effect than EGF and a longer duration of
action (Di Marco et al., 1990; Jankowski, 1994b).
In this studv the increased PxnrPccit-qn nf TC6Ftw ann
A B C EGFR in precancerous lesions correlates with observed
higher indices of proliferation in these lesions. In particular,
a shift in the compartmental position of the proliferating cells
to the upper compartment or throughout the gland was
b noted in areas of dysplasia and intestinal metaplasia of the
mcopiete type .3, WLJcn is associaea wiltn a iugner increased
risk of developing carcinoma than the complete type IM
(Rokkas et al.. 1991; Filipe et al., 1993, 1994).
In addition, the increased coexpression of EGFR TGF-a
in precancer stages suggest an aberrant autocrine loop which
may play a role in malignant transformation. Our data and
those of others indicate that the events leading to malignancy
follow a pathway initiated by microenvironmental damage,
leading to gastritis and a resistant metaplastic epithelium that
expresses TGF-a strongly. A combination of ligand and
receptor, such as TGF-a and EGFR, may subsequently lead
the cells to enter a final common pathway of oncogene
expression that results in breakdown of the normal feedback
control, leading ultimately to neoplasia and particularly the
intestinal type gastric carcinoma.
It is possible that the various stages of precancer are under
the influence of different mechanisms of growth regula-
tion:
(i) An inappropriate increase in functional molecules such as
EGFR at an early stage may lead to an enhanced production
of EGFR protein without negative feedback inhibition.
(ii) A change in autocrine or paracnne growth regulation at
an early/intermediate stage, may occur allowing TGF-x from
one cell to bind to EGFR on nearby cells; however, the
expression of TGF-x and EGFR would have to be very high
to counteract the effect of dilution of the ligand in the
extracellular space.
(iii) At a late stage synergism between growth-regulatory
molecules may stimulate cell proliferation and other
oncoerenes such as c-fos and c-mvc. as described in other
A B C gastrointestinal tumours (Di Marco et al., 1990; Tahara,
1990; Jankowski, 1994b).
Figure 8 TGF-a immunoreactivity in three paired specimens of
gastnc tissue intestinal metaplasia and gastnrc carcinoma with (a) Expression ofadditional growthfactors
and without (b) incubation with 50 yig of TGF-a peptide dunrng
immunostaining. It is clear that the TGF-a peptide markedly Other factors may also be involved in the process of gastric
reduces the immunoreactivity. carcinogenesis, and some may act at an early stage. (Tahara,9S~~~~~g*i wcanoma
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1990, 1993; Martin et al., 1992; Tohdo et al., 1993; Brito et
al., 1994; Jankowski, 1994b). Overexpression of Tpr-met
RNA has been detected in the earliest stage of superficial
gastritis with hyperplasia and is also present with variable
intensity in the various stages of progression to carcinoma,
suggesting the possible involvement of this oncogene in gas-
tric tumorigenesis (Soman et al., 1991).
Moreover, crypto, a gene of the EGF family, is over-
expressed in intestinal metaplasia as well as in well-
differentiated adenocarcinoma. Also of interest is that the
2.2 kb mRNA is detected in almost all intestinal metaplasias
and well-differentiated adenocarcinomas (Tahara, 1993).
These findings indicate that different genetic pathways of
stomach carcinogenesis may exist for well-differentiated and
poorly differentiated carcinomas. Some of the intestinal type
carcinomas may develop by a cumulative series of genetic
alterations similar to those that occur in colorectal cancer.
The exciting message is that increased knowledge of the
molecular events occurring in the precancer stage may have
important implications for the early detection of cancer risk
and for its prevention.
Conclusions and serial expression ofgrowthfactors during
tumorigenesis
Growth factors play an important role in the early stages and
progression of gastric carcinogenesis. Our data suggest a
potential role for quantitative/qualitative changes in growth
factors in gastric carcinogenesis. A possible hypothesis of
chronology of events could be as follows:
(i) + TGF-a and Tpr-met dunrng field defect.
(ii) + EGFR associated with the metaplastic
phenotype.
(iii) + TGF-a and EGFR with dysplasia.
(iv) + c-erbB2 with generation of invasive neoplasia.
(v) t EGF with advanced neoplasia and metastases.
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